Form 4 Filing for Aprea Therapeutics, Inc.

This filing details transactions by Rifat Pamukcu, a director at Aprea Therapeutics, Inc. On June 16, 2026, Pamukcu acquired 3,135 shares of Common Stock, bringing his direct holdings to 8,581 shares. This acquisition is noted as a restricted stock unit grant that will vest on June 16, 2027, contingent upon continued service. Additionally, Pamukcu acquired 12,555 stock options to buy Common Stock, with an exercise price of $0.7293, vesting on June 16, 2027. His indirect holdings through ZNZ Holdings LLC amount to 14,108 shares of Common Stock.